Dysregulation of Glutamine Utilization in the Pathogenesis of Multiple Myeloma

Description

This clinical trial studies the utilization of glutamine by the bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) compared to multiple myeloma (MM). Results from this study may identify metabolic differences between pre-malignant and malignant clonal plasma cells in MGUS and MM, respectively. It may also allow researchers better determine the transition from MGUS to MM for the development of potential early diagnostic purposes of preventative strategies.PRIMARY OBJECTIVE: I. Compare the glutamine anaplerosis activity in bone marrow clonal plasma cells (cPCs) between patients with MGUS and MM using an in vivo and an ex vivo approach. SECONDARY OBJECTIVES: I. Compare the tricarboxylic acid (TCA) isotopomer enrichment in the bone marrow plasma obtained from patients with MGUS and MM with the in vivo approach. II. Determine the peripheral blood enrichment of 13C in the TCA cycle intermediates from patients with MGUS and MM with the in

Trial Eligibility

Inclusion Criteria: * At least 18 years of age * International Myeloma Working Group (IMWG) criteria for the diagnosis of either MGUS or MM Exclusion Criteria: * Unable to provide consent * Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 3 * Hemoglobin \< 8 g/dL * Women who are pregnant * Prior history of adverse events with conscious sedation

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.